235 related articles for article (PubMed ID: 33262403)
1. Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.
Tsuchihashi K; Kusaba H; Yoshihiro T; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Imajima T; Shinohara Y; Ito M; Yamaga S; Tanoue K; Arimizu K; Ohmura H; Hanamura F; Yamaguchi K; Isobe T; Ariyama H; Nakashima Y; Akashi K; Baba E
Sci Rep; 2020 Dec; 10(1):20896. PubMed ID: 33262403
[TBL] [Abstract][Full Text] [Related]
2. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
[TBL] [Abstract][Full Text] [Related]
3. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Nakamura T; Asanuma K; Hagi T; Sudo A
Drug Des Devel Ther; 2020; 14():4215-4220. PubMed ID: 33116409
[TBL] [Abstract][Full Text] [Related]
5. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
[TBL] [Abstract][Full Text] [Related]
6. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.
Kobayashi E; Naito Y; Asano N; Maejima A; Endo M; Takahashi S; Megumi Y; Kawai A
Jpn J Clin Oncol; 2019 Oct; 49(10):938-946. PubMed ID: 31365116
[TBL] [Abstract][Full Text] [Related]
7. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
[TBL] [Abstract][Full Text] [Related]
8. Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma.
Kobayashi H; Okuma T; Oka H; Okajima K; Ishibashi Y; Zhang L; Hirai T; Ohki T; Tsuda Y; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Kawano H; Goto T; Tanaka S
Int J Clin Oncol; 2019 Apr; 24(4):437-444. PubMed ID: 30465138
[TBL] [Abstract][Full Text] [Related]
9. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
[TBL] [Abstract][Full Text] [Related]
10. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Inoue K; Takahashi M; Mukai H; Yamanaka T; Egawa C; Sakata Y; Ikezawa H; Matsuoka T; Tsurutani J
Invest New Drugs; 2020 Oct; 38(5):1540-1549. PubMed ID: 31950374
[TBL] [Abstract][Full Text] [Related]
12. Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment.
Takada K; Murase K; Nakamura H; Hayasaka N; Arihara Y; Iyama S; Ikeda H; Emori M; Sugita S; Nakamura K; Miyanishi K; Kobune M; Kato J
Intern Med; 2019 Oct; 58(20):3009-3012. PubMed ID: 31243217
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
14. Experience with eribulin in pretreated patients with advanced liposarcoma: a case series.
Paioli A; Setola E; Palmerini E; Cesari M; Longhi A
Future Oncol; 2020 Jan; 16(1s):25-32. PubMed ID: 31858818
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Katakami N; Felip E; Spigel DR; Kim JH; Olivo M; Guo M; Nokihara H; Yang JC; Iannotti N; Satouchi M; Barlesi F
Ann Oncol; 2017 Sep; 28(9):2241-2247. PubMed ID: 28911085
[TBL] [Abstract][Full Text] [Related]
16. Eribulin in soft-tissue sarcomas.
Maki RG
Lancet Oncol; 2011 Oct; 12(11):988-9. PubMed ID: 21937276
[No Abstract] [Full Text] [Related]
17. Tumor Lysis Syndrome due to Eribulin Administration for Metastatic Undifferentiated Pleomorphic Sarcoma of the Buttock.
Tsuchie H; Miyakoshi N; Nagasawa H; Shimada Y
Acta Med Okayama; 2021 Aug; 75(4):533-538. PubMed ID: 34511623
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ratan R; Patel SR
Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
[TBL] [Abstract][Full Text] [Related]
20. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]